Clinical Trial Update: Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension [Phase 3]

View source ↗

Summary

Open-label Phase 3 extension study evaluating oral levosimendan effects on respiratory function in Amyotrophic Lateral Sclerosis was terminated; results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2023-03-09